B & V PHARMA
Board
2 directors, last change in 2023Director (not named in the articles)
since 19-10-2022
term without a fixed end
earlier manager, until 26-01-2023
listed in the 2025 annual accounts, filed on 18-06-2026
Director (not named in the articles)
since 19-10-2022
term without a fixed end
earlier manager, until 26-01-2023
listed in the 2025 annual accounts, filed on 18-06-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 26-01-2023
Mandates through the years
2 names, the dashed line is todayDirector (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
-
- Director (not named in the articles), since before 31-12-2021
- Manager, until 26-01-2023
-
- Director (not named in the articles), since before 31-12-2021
- Manager, until 26-01-2023
With Starter you also see 1 former office holder in the mandate history.
See the plans →
Control
Shareholders
, ,
This company
B & V PHARMA
Equity €939,237
Profit €213,775 in 2025
Capital
- Contribution
- €6,200
- Source
- 2025 annual accounts
Articles of association
deed of 26-01-2023 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- First Friday of June at 20:00
Shareholders
Stated in the deed
deed of 25-03-2014 ↗
- 4 shares
- 4 shares
- 786 shares
Capital transactions
Capital over time
- 26-01-2023 Converted to unavailable equity
- 25-01-2018 Capital reduction of €369,000 · to €18,600
- 25-03-2014 Capital increase of €369,000 · to €387,600 · 794 new shares · “inbreng zekere vaststaande opeisbare schuldvordering 90 procent vordering uitkering tussentijds dividend”